1. Construction and mouse antibody response evaluation of juvenile stage-specific chimeric protein from Fasciola gigantica.
- Author
-
Cheukamud W, Chansap S, Rattanasroi K, Changklungmoa N, and Kueakhai P
- Subjects
- Animals, Mice, Male, Fascioliasis veterinary, Fascioliasis prevention & control, Fascioliasis immunology, Immunoglobulin G blood, Antigens, Helminth immunology, Antigens, Helminth genetics, Immunization veterinary, Recombinant Fusion Proteins immunology, Recombinant Fusion Proteins genetics, Antibody Formation, Fasciola immunology, Fasciola genetics, Mice, Inbred BALB C, Antibodies, Helminth blood, Helminth Proteins immunology, Helminth Proteins genetics
- Abstract
Fasciolosis, caused by the liver fluke Fasciola gigantica, is a major parasitic disease that affects livestock and therefore causes significant economic losses in tropical countries. Although anthelminthic drugs can kill the parasite, drug-resistant liver fluke populations are increasing. In this study, a recombinant F. gigantica chimeric protein (rFgCHI) consisting of cathepsin L1H (FgCL1H), cathepsin B3 (FgCB3), and Saposin-like protein 1 (FgSAP1) was designed and expressed in Escherichia coli (BL21). The molecular weight of rFgCHI was 61 kDa. To study the antibody response, male BALB/c mice were immunized via the subcutaneous injection of rFgCHI combined with Quil A. Immunization with rFgCHI showed the induction of IgG1 and IgG2a with a higher IgG1 isotype level, indicating the potential of mixed Th1/Th2 immune responses, with Th2 predominating. However, the results showed high levels of IgG against the single proteins, except for rFgSAP1. Through Western blotting, mouse anti-rFgCHI polyclonal antibodies could be detected to the native proteins obtained from the parasite at all stages. Immunolocalization also revealed that the anti-rFgCHI antibodies could detect targeted antigens in the cecal epithelium of the parasite. These results demonstrated that rFgCHI is immunogenic to the mouse immune system and may potentially be a protein candidate for the development of a fasciolosis vaccine., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Pornanan Kueakhai reports financial support was provided by Thailand Research Fund. Pornanan Kueakhai has patent #2303003287 pending to Thailand Science Research and Innovation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF